CarelonRx's DrugInsights provides a quarterly summary of Food and Drug Administration (FDA)-approved new molecular entities, formulations, and indications. We continue to closely monitor the FDA landscape to help provide our audiences with an understanding of the current drug and biologic market.
Download the PDF to access the Q2 2025 DrugInsights update.
You may also be interested in:
Enhancing health outcomes through community pharmacy care
From pipeline to prescription: the formulary development process at CarelonRx
